Glafabra Welcomes Elizabeth Wagner to Advisory Board
Glafabra Therapeutics is pleased to announce the addition of Elizabeth Wagner to its team as a key advisor with a focus on further enhancing the company's cell therapy portfolio. With her extensive background and a proven track record of successful operational development, Elizabeth is set to bring a wealth of expertise to Glafabra Therapeutics.
"I am thrilled to join the team at Glafabra Therapeutics and contribute to the advancement of their innovative Live-cel therapy initiatives," said Elizabeth Wagner. “Live-cel therapy is exciting because it uses the patients own cells that have been corrected. They now express the protein missing in the patient and we put those modified cells back into the patient to achieve long lasting effect. One dose can last at least 5 years as reported in the team’s peer-reviewed publication that came out this year.”
Prior to joining Glafabra Therapeutics, Elizabeth served as the Chief Operating Officer at Constant Therapeutics, where she played a pivotal role in steering the company's strategic operational activities. Her leadership led to significant accomplishments, including the successful coordination of preclinical and clinical research activities resulting in three assets achieving progressing to Phase 2 and an additional oral formulation program through GMP production.
"I look forward to leveraging my experience in portfolio strategy and operational development to drive continued growth and success at Glafabra Therapeutics," added Elizabeth.
Elizabeth's impressive career also includes roles at renowned pharmaceutical companies such as Cubist Pharmaceuticals, Genentech, and Genzyme, where she honed her skills in corporate development, pipeline and portfolio planning, and clinical research. Her academic qualifications include a MBA and MS from Massachusetts Institute of Technology.
"We are thrilled to welcome Elizabeth Wagner to our team. We are confident that her leadership and expertise will play a pivotal role in advancing our rare disease portfolio," stated Dr. Chris Hopkins, CEO of Glafabra Therapeutics.
About Glafabra
Glafabra has developed Live-cell Technologies - A One Treatment for a Lifetime of Relief. Patients with genetic disease recieve an autologous-derived cell therapy product to achived durable restoration of the missing protein activity. In a pilot trial, glafabra’s lead asset is clinically-demonstrated for Fabry disease with the potential to be safe, effective and highly durable with Glafabra’s GLA-CT-S03 Live-cell therapy. Five patients were safely and effectively treated with GLA-CT-S03 in the team’s published, peer-reviewed FACTS trial report (PMID 39794302). GLA-CT-S03 will be repeatable as per needed while serving a significant portion of an established $1 B/y market. Glafabra’s Live-cel therapies for Fabry, Gaucher and Pompe metabolic disorders are expected to be a highly effective and, with one procedure, patients will be able to achieve a lifestyle normality that can last a lifetime.
For more information, contact us at info@glafabra.com
